SAN FRANCISCO, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced the appointment of Anil Kapur to its board of directors, effective October 15, 2024. Mr. Kapur has over 25 years of executive experience in pharmaceutical and biotech companies across both U.S. and international markets. "I am delighted to welcome Anil ...

Nurix Therapeutics, Inc. (NRIX) came out with a quarterly loss of $0.67 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.68 per share a year ago. These figures are adjusted for nonrecurring items. A quarter ago, it was expected that this company would post a loss of $0.66 per share when it actually produced a loss of $0.71, delivering a surprise of -7.58%. Over the last four quarters, the company has surpassed consensus EPS estimates just once. Nurix Therapeutics, which belon ...

Table of Contents Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share NRIX Nasdaq Global Market UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ______________________________________________________________________ FORM 10-Q ______________________________________________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF ...

Exhibit 99.1 [Nurix logo] Nurix Therapeutics Reports Third Quarter Fiscal 2024 Financial Results and Provides a Corporate Update Initiated Phase 1b dose expansion of NX-5948 in chronic lymphocytic leukemia patient population with Fast Track Designation from the FDA Initiated Phase 1b dose expansion of NX-5948 in Waldenstrom's macroglobulinemia, follicular lymphoma and marginal zone lymphoma patients Reinitiated enrollment for NX-2127 in a Phase 1a/b trial in oncology Presented preclinical data on Degrader-A ...

Initiated Phase 1b dose expansion of NX-5948 in chronic lymphocytic leukemia patient population with Fast Track Designation from the FDA Initiated Phase 1b dose expansion of NX-5948 in Waldenstrom's macroglobulinemia, follicular lymphoma and marginal zone lymphoma patients Reinitiated enrollment for NX-2127 in a Phase 1a/b trial in oncology Presented preclinical data on Degrader-Antibody Conjugates (DACs), a new class of therapeutics Well capitalized with cash and marketable securities of $457.5 million SAN ...

koto_feja I covered Nurix Therapeutics, Inc. (NASDAQ:NRIX) over a year ago, and in this article, besides giving an update, I'm also going to take a look at the science behind small molecule BTK degradation and emerging competition in the field. About Nurix Nurix has been around for 15 years, but IPO-ed just four years ago. I covered it from the beginning, and in that time, the stock and the market cap have seen multifold increases. The current market cap is a decent $1.6bn, despite the latest programs being ...

SAN FRANCISCO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that Arthur T. Sands, M.D, Ph.D., president and chief executive officer of Nurix, Hans van Houte, chief financial officer of Nurix, and Jason Kantor, Ph.D., chief business officer of Nurix, will participate in the following conferences in September: 20 ...

Shares of Nurix Therapeutics, Inc. (NRIX) have gained 3.1% over the past four weeks to close the last trading session at $21.09, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $26.42 indicates a potential upside of 25.3%. The mean estimate comprises 12 short-term price targets with a standard deviation of $5.95. While the lowest estimate of $15 indicates a 28.9% decline from th ...

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In the 'long' context, investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades. Even though momentum is a popular stock cha ...

Nurix Therapeutics shares have added about 96.1% since the beginning of the year versus the S&P 500's gain of 18.1%. It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.69 on $15.84 million in revenues for the coming quarter and -$2.85 on $64.98 million in revenues for the current fiscal year. This biopharmaceutical company is expected to post quarterly earnings of $1.66 per share in its upcoming repo ...